TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 0.25nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 0.25nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 0.260nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 0.300nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 0.380nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 0.380nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 0.460nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 0.700nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 0.700nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 0.800nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 0.900nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 5nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 6nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 8nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 23nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 36nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 37nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 37nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 40nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 55nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 78nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 130nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 200nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 460nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 470nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 1.90E+3nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: 2.00E+3nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+4nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair
TargetIntegrin alpha-V/beta-3(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataIC50: >2.00E+4nMAssay Description:Inhibitory concentration against alphaV-beta3 integrinMore data for this Ligand-Target Pair